Updated: Nov 19
This free educational article is brought to you by the Higher Learning LV seminar Cannabis for Cancer. This exclusive and affordable $80 seminar is based on the latest scientific research studies and provides students with a comprehensive understanding of how cannabis may help some cancer patients gain relief.
Survey of CBG Patients
An October 2022 study entitled "Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms" that was published in the journal Cannabis and Cannabinoid Research explored the potential medicinal efficacy of the cannabis- and hemp-derived cannabinoid cannabigerol (CBG).
The study's authors—who included cannabis research pioneer Dr. Ethan Russo—stated that the purpose of their scientific investigation was to explore "reasons for use and self-reported therapeutic effects in CBG-predominant cannabis users." The researchers observed CBG usage patterns and looked for potential adverse effects, including withdrawal symptoms (spoiler: very found were found).
Survey of CBG Patients Conclusions
Survey of CBG Patients. "Most of the participants (51 percent) reported use of CBG-predominant products solely for medical purposes (36 percent reported use for medical and recreational purposes; six percent reported recreational use only).
The most common conditions the study subjects reported using CBG to treat were:
Efficacy was highly rated, with the majority reporting their conditions were 'very much improved' or 'much improved' by CBG. Furthermore, [many study participants] claimed superiority of CBG-predominant cannabis over conventional medicines for:
Chronic pain (74%)
Forty-four percent of CBG-predominant cannabis users reported no adverse events, with [the following adverse events]:
Dry mouth (17%)
Increased appetite (12%)
Dry eyes (9%)
"Around 84 percent reported no withdrawal symptoms, with sleep difficulties representing the most frequently endorsed withdrawal symptom (endorsed by two respondents).
"Perceived efficacy was highly rated, with the majority reporting their conditions were 'very much improved' or 'much improved' by CBG."
"This is the first patient survey of CBG-predominant cannabis use to date and the first to document self-reported efficacy of CBG-predominant products, particularly for anxiety, chronic pain, depression, and insomnia. Most respondents reported greater efficacy of CBG-predominant cannabis over conventional pharmacotherapy, with a benign (safe) adverse event profile and negligible withdrawal symptoms.
"This study establishes that humans are employing CBG and suggests that CBG-predominant cannabis-based medicines should be studied in randomized controlled trials."
Did you enjoy Survey of CBG Patients (2022)? Are you a cannabis industry professional? Check out Higher Learning LV's Deep Dive Subscription that features dozens of long-form articles based on the latest peer-reviewed scientific research. Priced to accommodate personal and enterprise training budgets.